<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040660</url>
  </required_header>
  <id_info>
    <org_study_id>MW2018-06-21</org_study_id>
    <nct_id>NCT04040660</nct_id>
  </id_info>
  <brief_title>Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries</brief_title>
  <acronym>NEXT</acronym>
  <official_title>Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediWound Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MediWound Ltd</source>
  <brief_summary>
    <textblock>
      Enzymatic eschar removal with NexoBrid allows initiating and completing the phase of removal&#xD;
      of the offending eschar earlier upon admission, enabling earlier visualization of the wound&#xD;
      bed for assessment of burn wound depth as well as preservation of viable dermal tissues, as&#xD;
      further elaborated and supported by previous clinical studies. The depth determination is&#xD;
      important for the planning and execution of the post eschar removal stage of wound closure&#xD;
      phase (grafting or spontaneous epithelialization).&#xD;
&#xD;
      Additional clinically meaningful attributes of NexoBrid enzymatic eschar removal is the&#xD;
      ability to lower surgical burden as it allows to remove eschar in wounds that otherwise would&#xD;
      have to undergo surgical excision as no other non-surgical treatment is available for early&#xD;
      and effective eschar removal.&#xD;
&#xD;
      MediWound has completed the recruitment of patients to study MW2010-03-02 (DETECT Study). The&#xD;
      timeline for patients' follow-up and potential for approval in 2021/2022, creates a&#xD;
      significant gap in the ability of clinical practitioner's to maintain their knowledge and&#xD;
      skills in using NexoBrid as they no longer treat eligible patients. The expanded access&#xD;
      protocol will allow to expand treatment to additional patients in up to 30 US burn centers&#xD;
      (DETECT sites and additional sites), until the completion of the BLA assessment and possible&#xD;
      marketing authorization of NexoBrid in the US. The proposed protocol will allow product&#xD;
      availability to eligible population and keep the clinical use of the product knowledge active&#xD;
      in the burn care community introducing it to their routine burn care.&#xD;
&#xD;
      The purpose of this treatment protocol is to provide NexoBrid to patients with DPT and FT&#xD;
      thermal burns on up to 30% TBSA.&#xD;
&#xD;
      This protocol is also designed to collect and evaluate the safety and clinical performance of&#xD;
      NexoBrid in this patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an Expanded Access (treatment) protocol to allow ongoing treatment of burn patients&#xD;
      with NexoBrid following completion of the enrollment stage of protocol MW2010-03-02 (DETECT&#xD;
      study).&#xD;
&#xD;
      This protocol is also designed to collect and evaluate the safety and clinical performance of&#xD;
      NexoBrid in patients suffering from DPT and FT thermal burns.&#xD;
&#xD;
      Following the enrollment of a patient to the protocol, physicians will identify one or more&#xD;
      target wounds (TWs) per patient according to the TW definition. All patient's DPT and FT&#xD;
      burns that comply with the specified entrance criteria will be treated with NexoBrid and,&#xD;
      therefore, must be designated as TWs. This will further allow an evaluation of the patient's&#xD;
      systemic safety by allowing treatment of the patient's entire deep burns.&#xD;
&#xD;
      Prior to initiation of eschar removal treatment, patients will be medicated with appropriate&#xD;
      analgesia and undergo wound cleansing and dressing of all wounds with antibacterial solutions&#xD;
      according to product instruction for use in order to ensure clean and moist eschar covered&#xD;
      wound bed for NexoBrid application. Vital signs (Blood Pressure, Heart Rate and temperature)&#xD;
      measurements and pain assessment will be performed within 24 hrs before start of treatment as&#xD;
      well as haematology, biochemistry blood tests &amp; PTT/INR. Pressure measurements for&#xD;
      circumferential extremity wounds will be performed 1 hour before start of treatment and will&#xD;
      be closely monitored during treatment. Following wound cleansing and soaking treatments,&#xD;
      patients will undergo the eschar removal process. TWs of up to 15% total body surface area&#xD;
      (TBSA) will be treated with a single application of NexoBrid for 4 hours. Patients with TWs&#xD;
      &gt;15% TBSA and up to 30% TBSA will be treated with 2 consecutive applications of 4 hours each.&#xD;
      NexoBrid should not be applied to more than 15% TBSA in one session. PK samples will be taken&#xD;
      from sub-set of patients with TWs area &gt;15% TBSA. Pressure measurements for circumferential&#xD;
      extremity wounds will be performed after the removal of NexoBrid.&#xD;
&#xD;
      Post eschar removal completion, patients will undergo daily vital signs (Blood Pressure,&#xD;
      Heart Rate and temperature measurements) and pain assessments for 1 week, starting on the&#xD;
      morning following start of eschar removal. Blood tests (haematology and biochemistry) will be&#xD;
      performed 24 ± 6 hrs post eschar removal as well as PTT/INR. Weekly assessments of wound&#xD;
      healing progress including the dressings used until complete wound closure will be performed.&#xD;
&#xD;
      Cosmesis (scar quality) evaluation (using MVSS) will be performed at 3 and 12 months post&#xD;
      wound closure confirmation visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Thermal Burn</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NexoBrid</intervention_name>
    <description>NexoBrid is presented as lyophilized powder and gel vehicle for preparation of a gel for cutaneous use. The API is a concentrate of proteolytic enzymes enriched in Bromelain extracted from the stem of Ananas comosus (pineapple plant)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria patient level:&#xD;
&#xD;
          1. Males and females ≥ 18 years of age,&#xD;
&#xD;
          2. Thermal burns caused by fire/flame, scalds or contact,&#xD;
&#xD;
          3. Patient total burns area ≥ 1% DPT and / or FT with eschar that should be removed in&#xD;
             SOC,&#xD;
&#xD;
          4. Patient total burns area to be treated should be ≤ 30% TBSA; SPT, DPT and/or FT in&#xD;
             depth,&#xD;
&#xD;
          5. Informed consent can be obtained within 84h of the burn injury,&#xD;
&#xD;
          6. Patients who are willing and able to sign a written consent . Inclusion Criteria -&#xD;
             Wound level&#xD;
&#xD;
               -  At least one wound (a continuous burn area) that is ≥0.5% TBSA (DPT and/or FT)&#xD;
                  (this minimal wound size should not include face, perineal or genital)&#xD;
&#xD;
        All planned TWs should meet the following criteria:&#xD;
&#xD;
          -  SPT areas that cannot be demarcated from DPT and FT areas should be less than 50% of&#xD;
             the % TBSA of the TW, with eschar that should be removed in SOC,&#xD;
&#xD;
          -  Wound's blisters can be removed/ unroofed, as judged by the investigator.&#xD;
&#xD;
        Exclusion Criteria patient level:&#xD;
&#xD;
          1. Modified Baux index ≥ 80,&#xD;
&#xD;
          2. Patients with burned, charred fingers, 3rd degree in depth and possibly devoid of&#xD;
             circulation,&#xD;
&#xD;
          3. Patients with abraded wound/s that cannot be treated by an enzymatic debrider&#xD;
             application (NexoBrid),&#xD;
&#xD;
          4. Patients with pre enrolment escharotomy,&#xD;
&#xD;
          5. Patients with electrical or chemical burns,&#xD;
&#xD;
          6. The following pre-enrollment dressings: a. Flammacerium, b. Silver Nitrate (AgNO3),&#xD;
&#xD;
          7. Patients with pre-enrolment wounds which are covered by eschar heavily saturated with&#xD;
             Silver, Iodine or by SSD pseudoeschar (pseudoeschar as a result of &gt; 12 hrs SSD&#xD;
             treatment),&#xD;
&#xD;
          8. Patients with diagnosed infections as described in the protocol,&#xD;
&#xD;
          9. Diagnosis of smoke inhalation injury [12],&#xD;
&#xD;
         10. Pregnant women (serum positive pregnancy test) or nursing mothers,&#xD;
&#xD;
         11. Poorly controlled diabetes mellitus (HbA1c&gt;11%) in patients with known diabetes as&#xD;
             captured in the medical history,&#xD;
&#xD;
         12. BMI greater than 39.0 kg/m2 in patients with burns area of up to 15% TBSA or BMI&#xD;
             greater than 34.0 kg/m2 in patients with burns area of more than 15% %TBSA,&#xD;
&#xD;
         13. American Society of Anesthesiologists (ASA) physical status classification system&#xD;
             greater than 2&#xD;
&#xD;
         14. Cardio-pulmonary disease (MI within 6 months prior to injury, severe or unstable&#xD;
             Ischemic Heart Disease, severe or unstable heart failure, severe pulmonary&#xD;
             hypertension, severe COPD or pre-existing oxygen-dependent pulmonary diseases, severe&#xD;
             broncho-pneumonia within 1 month prior to injury, steroid dependent asthma or&#xD;
             uncontrolled asthma),&#xD;
&#xD;
         15. Pre-existing diseases which interfere with circulation (severe peripheral vascular&#xD;
             disease, severe circulatory edema and/or lymphedema, regional lymph nodes dissection,&#xD;
             significant varicose veins),&#xD;
&#xD;
         16. Any conditions that would preclude safe treatment or adding further risk to the basic&#xD;
             acute burn trauma (such as severe immuno-compromising diseases, life threatening&#xD;
             trauma, severe pre-existing coagulation disorder, severe cardiovascular disorder,&#xD;
             significant pulmonary disorder, significant liver disorder including post alcoholic&#xD;
             abuse impaired function or neoplastic disease, blast injury),&#xD;
&#xD;
         17. Chronic systemic steroid intake,&#xD;
&#xD;
         18. History of allergy and/or known sensitivity to pineapples, papaya, Bromelain or&#xD;
             papain.&#xD;
&#xD;
         19. Enrollment in any investigational drug trial within 4 weeks prior to screening.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Limor Klein, PhD</last_name>
    <phone>972-77-9714176</phone>
    <email>limord@mediwound.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keren David-Zarbiv</last_name>
    <phone>972-77-9714103</phone>
    <email>kerend@mediwound.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Andrew Bright, DO</last_name>
      <phone>251-471-7971</phone>
      <email>abright@health.southalabama.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kelley Prutzman, RN</last_name>
    </contact_backup>
    <investigator>
      <last_name>Andrew Bright, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maricopa Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Kevin Foster, MD</last_name>
      <phone>602-344-5624</phone>
      <email>kevin_foster@dmgaz.org</email>
    </contact>
    <contact_backup>
      <last_name>Suzanne Osborne, RN</last_name>
      <phone>602-344-5141</phone>
      <email>suzanne.osborn@mihs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin Foster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medstar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jeffrey Shupp, MD</last_name>
      <phone>202-877-7347</phone>
      <email>jeffrey.w.shupp@medstar.net</email>
    </contact>
    <contact_backup>
      <last_name>Melissa McLawhorn</last_name>
      <phone>202-877-6181</phone>
      <email>Melissa.M.Mclawhorn@medstar.net</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Shupp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Joshua Carson, MD</last_name>
      <email>Joshua.Carson@surgery.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tera Thigpin</last_name>
      <phone>352-265-0111</phone>
      <email>tera.thigpin@surgery.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joshua Carson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Louis Pizano, MD</last_name>
      <phone>305-585-1178</phone>
      <email>lpizano@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ron Manning</last_name>
      <phone>305-355-4990</phone>
      <email>rmanning@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Louis Pizano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>lucy wibbenmeyer, MD</last_name>
      <phone>319-356-3551</phone>
      <email>lucy-wibbenmeyer@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Morgan</last_name>
      <phone>319-356-1304</phone>
      <email>elizabeth-morgan@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>lucy wibbenmeyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Lucy Wibbenmeyer, MD</last_name>
      <phone>319-356-1304</phone>
      <email>lucy-wibbenmeyer@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Burnett Burn Center at The University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Dhaval Bhavsar, MD</last_name>
      <phone>913-588-2000</phone>
      <email>dbhavsar@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Reynolds, RN</last_name>
      <phone>913-588-0068</phone>
      <email>jreynolds11@kumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dhaval Bhavsar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Burn Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Julie Caffrey, MD</last_name>
      <email>jcaffre5@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vidhi Javia</last_name>
      <phone>443-287-7848</phone>
      <email>vjavia1@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Julie Caffrey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The General Hospital Corporation d/b/a Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jeremy Goverman, MD</last_name>
      <phone>617-726-3712</phone>
      <email>JGOVERMAN@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Levin, RN</last_name>
      <email>Jlevin7@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jeremy Goverman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hennepin Healthcare</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Frederick Endorf, MD</last_name>
      <email>Frederick.Endorf@hcmed.org</email>
    </contact>
    <contact_backup>
      <last_name>Emily Kittelson</last_name>
      <phone>612-873-6396</phone>
      <email>Emily.Kittelson@hcmed.org</email>
    </contact_backup>
    <investigator>
      <last_name>Frederick Endorf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Missouri Health Care</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jeffrey Litt, DO</last_name>
      <phone>573-884-6779</phone>
      <email>littjs@health.missouri.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Randolph, RN</last_name>
      <phone>573-882-4387</phone>
      <email>randolphjl@health.missouri.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Litt, MO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New-York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>James Gallagher, MD</last_name>
      <phone>212-746-7913</phone>
      <email>jag9027@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Angela Rabbitts, RN</last_name>
      <phone>212-746-5881</phone>
      <email>anr2002@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James Gallagher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emergency Medicine Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Adam Singer, Dr</last_name>
      <phone>631-444-7857</phone>
      <email>adam.singer@stonybrookmedicine.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maria (Merry) Taylor, RN</last_name>
      <phone>631-444-8345</phone>
      <email>PhaMaria.Taylor@stonybrookmedicine.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Oregon Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>972227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Kristin Hickey</last_name>
      <phone>503-413-5447</phone>
    </contact>
    <investigator>
      <last_name>Michael J Mosier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital and Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Sigrid Blome-Eberwein, MD</last_name>
      <phone>610-402-1485</phone>
      <email>Sigri.Blome-Eberwein@lvhn.org</email>
    </contact>
    <contact_backup>
      <last_name>Mary Sobotor, CCRC</last_name>
      <phone>610-402-1592</phone>
      <email>Mary.Sobotor@lvhn.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sigrid Blome-Eberwein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Firefighters Regional Burn Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>William Hickerson, MD</last_name>
      <phone>901-448-2579</phone>
      <email>whicker@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>William Hickerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Giavonni Lewis, MD</last_name>
      <phone>801-581-8990</phone>
      <email>giavonni.lewis@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Martin Carricaburu</last_name>
      <phone>801-581-3363</phone>
      <email>martin.carricaburu@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Giavonni Lewis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Tam Pham, MD</last_name>
      <phone>206-744-3140</phone>
      <email>tpham94@uw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emily Eschelbach, RN</last_name>
      <phone>206-744-3587</phone>
      <email>eschee13@uw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tam Pham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colombia St Mary's, Inc.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Nicholas Meyer, MD</last_name>
      <email>whicker@uthsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Margaret Wilson</last_name>
      <phone>414-585-1498</phone>
      <email>Margaret.Wilson2@ascension.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nicholas Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

